Pharsight

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9006289	January, 2017	Terminated-Settled	Fresenius Kabi USA, LLC	Mylan Institutional Inc.
US9168238	January, 2017	Terminated-Settled	Fresenius Kabi USA, LLC	Mylan Institutional Inc.
US9168239	January, 2017	Terminated-Settled	Fresenius Kabi USA LLC	Mylan Institutional Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238	FRESENIUS KABI USA	Levothyroxine formulations	Aug, 2032 (8 years from now)
US9168239	FRESENIUS KABI USA	Levothyroxine formulations	Aug, 2032 (8 years from now)
US9006289	FRESENIUS KABI USA	Levothyroxine formulations	Oct, 2032 (8 years from now)
US9782376	FRESENIUS KABI USA	Levothyroxine liquid formulations	Dec, 2036 (12 years from now)
US11135190	FRESENIUS KABI USA	Levothyroxine liquid formulations	Dec, 2036 (12 years from now)
US10398669	FRESENIUS KABI USA	Levothyroxine liquid formulations	Dec, 2036 (12 years from now)

Levothyroxine Sodium is owned by Fresenius Kabi Usa.

Levothyroxine Sodium contains Levothyroxine Sodium.

Levothyroxine Sodium has a total of 6 drug patents out of which 0 drug patents have expired.

Levothyroxine Sodium was authorised for market use on 24 June, 2011.

Levothyroxine Sodium is available in solution;intravenous, powder;intravenous dosage forms.

The generics of Levothyroxine Sodium are possible to be released after 01 December, 2036.

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 mcg/vial and 500 mcg/vial	14 Apr, 2015	2	29 Jun, 2016	03 Oct, 2032	Eligible
200 mcg/vial	01 May, 2015	1	07 Dec, 2015	03 Oct, 2032	Deferred

LEVOTHYROXINE SODIUM family patents

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154498	HIKMA	Stabilized liquid formulation of levothyroxine	Jul, 2036 (12 years from now)

Levothyroxine Sodium is owned by Hikma.

Levothyroxine Sodium contains Levothyroxine Sodium.

Levothyroxine Sodium has a total of 1 drug patent out of which 0 drug patents have expired.

Levothyroxine Sodium was authorised for market use on 17 May, 2021.

Levothyroxine Sodium is available in solution;intravenous dosage forms.

The generics of Levothyroxine Sodium are possible to be released after 20 July, 2036.

Market Authorisation Date: 17 May, 2021

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS